1. Show article details.

    BRIEF-Agenus's Chairman And CEO Said He Would Take His Salary In Stock In Lieu Of Cash For Rest Of 2020

    Reuters – 9:12 AM ET 03/30/2020

    Agenus Inc (AGEN): * Agenus Inc (AGEN) - GARO ARMEN, CHAIRMAN AND CEO INDICATED HE WOULD TAKE HIS SALARY IN STOCK IN LIEU OF CASH FOR REST OF 2020. * Agenus Inc (AGEN) - IMPLEMENTED PROACTIVE MEASURES IN RESPONSE TO CHANGING BUSINESS ENVIRONMENT AS A CONSEQUENCE OF COVID-19 PANDEMIC.

  2. Show article details.

    BRIEF-Agenus Reports Q4 Loss Per Share Of $0.22

    Reuters – 9:46 AM ET 03/12/2020

    Agenus Inc (AGEN): * AGENUS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE. * Q4 LOSS PER SHARE $0.22. * Q4 EARNINGS PER SHARE ESTIMATE $-0.38 -- REFINITIV IBES DATA. * EXPECT CASH BALANCE TO BE IN EXCESS OF $100M AT END OF Q1 OF 2020 Source text for Eikon: Further company coverage:

  3. Show article details.

    BRIEF-Agenus Receives Fast Track Designation For Balstilimab & Zalifrelimab In Advanced Cervical Cancer

    Reuters – 8:16 AM ET 03/12/2020

    Agenus Inc (AGEN): * AGENUS RECEIVES FAST TRACK DESIGNATION FOR BALSTILIMAB & ZALIFRELIMAB IN ADVANCED CERVICAL CANCER. * Agenus Inc (AGEN) - EXPECTS TO FILE 2 BLAS THIS YEAR FOR ACCELERATED APPROVAL OF COMBINATION OF BALSTILIMAB AND ZALIFRELIMAB AND BALSTILIMAB MONOTHERAPY Source text for Eikon: Further company coverage:

  4. Show article details.

    Agenus Receives Fast Track Designation for Balstilimab & Zalifrelimab in Advanced Cervical Cancer

    PR Newswire – 7:45 AM ET 03/12/2020

    LEXINGTON, Mass. "We are pleased that balstilimab and zalifrelimab have been granted Fast Track designation by FDA in recognition of the high unmet medical need in second line cervical cancer. Agenus (AGEN) has reported updated data from a pre-planned interim analysis revealing robust and durable activity of balstilimab and zalifrelimab in patients with relapsed or refractory metastatic cervical cancer.

  5. Show article details.

    Agenus Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

    PR Newswire – 7:30 AM ET 03/12/2020

    LEXINGTON, Mass. "We are excited by the clinical responses seen in our phase 1 trial of AGEN1181 alone and in combination with our PD-1," said Garo Armen, Ph.D., Chairman and CEO, Agenus.

  6. Show article details.

    First QS-21 Royalty Payment Due to Agenus is Triggered

    PR Newswire – 9:14 AM ET 03/10/2020

    LEXINGTON, Mass. Agenus' (AGEN) proprietary QS-21 Stimulon™ is one of the most potent adjuvants known and is a key component in GSK's Shingrix vaccine, which has generated blockbuster sales exceeding $2.3Bn in its second year after launch.

  7. Show article details.

    Agenus to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020 with Conference Call and Webcast

    PR Newswire – 8:00 AM ET 03/03/2020

    LEXINGTON, Mass. Conference Call and Webcast Information:Date: Thursday, March 12, 2020Time: 8:30 a.m. ETDomestic Dial-in Number: 1-844-492-3727International Dial-in Number: 1-412-317-5118Conference ID: Agenus.

  8. Show article details.

    BRIEF-Agenus Announces Positive Interim Data From Balstilimab And Zalifrelimab Clinical Trials In Second-Line Cervical Cancer

    Reuters – 12:27 PM ET 02/20/2020

    Agenus Inc (AGEN): * AGENUS ANNOUNCES POSITIVE INTERIM DATA FROM BALSTILIMAB AND ZALIFRELIMAB CLINICAL TRIALS IN SECOND-LINE CERVICAL CANCER. * Agenus Inc (AGEN) - BALSTILIMAB AND ZALIFRELIMAB COMBINATION YIELD MORE THAN 20% RESPONSE RATES. * Agenus Inc (AGEN) - ON TRACK TO SUBMIT 2 BLAS FOR THESE AGENTS IN 2020.

  9. Show article details.

    Agenus Announces Positive Interim Data from Balstilimab and Zalifrelimab Clinical Trials in Second-Line Cervical Cancer

    PR Newswire – 9:56 AM ET 02/20/2020

    LEXINGTON, Mass. The interim analysis from 34 evaluable patients treated with the combination of balstilimab  and zalifrelimab demonstrated a 20.6% overall response rate, which included a complete response rate of 8.8% in second-line cervical cancer.

  10. Show article details.

    Agenus Announces Investor Day on February 20, 2020

    PR Newswire – 3:12 PM ET 02/06/2020

    LEXINGTON, Mass.

  11. Show article details.

    Agenus Announces the Appointment of Dr. Jennifer Buell to the position of President and COO

    PR Newswire – 10:59 AM ET 01/09/2020

    LEXINGTON, Mass. "Jen's tenure with Agenus (AGEN), her exceptional leadership and cultural attributes, and her deep understanding of our science and operations makes her the top candidate for this newly created position," said Garo H. Armen, Ph.D., Chairman and CEO of Agenus (AGEN). After her tenure at Harvard Clinical Research Institute, Dr. Buell rejoined Agenus (AGEN) in 2013 as the Head of Global R&D operations.

  12. Show article details.

    Biotechnological Breakthroughs Help Revamp the Fight Against Cancer

    PR Newswire – 9:21 AM ET 01/09/2020

    NEW YORK, Jan. 9, 2020 Biotechnology plays an important role throughout various sectors by improving industry standards, services, and developing new products. Overall, the cancer treatment market is one of the biggest segments of the biotechnology industry.

  13. Show article details.

    BRIEF-Agenus Commences Phase 1 Trial With Agen1223

    Reuters – 8:47 AM ET 01/08/2020

    Agenus Inc (AGEN): * AGENUS COMMENCES PHASE 1 TRIAL WITH AGEN1223. * Agenus Inc (AGEN) - FIRST PATIENT DOSED FOR PHASE 1 TRIAL WITH AGEN1223; COMBINATIONS WITH OTHER IO AGENTS PLANNED FOR 2020 Source text for Eikon: Further company coverage:

  14. Show article details.

    Agenus Commences Phase 1 trial with AGEN1223

    PR Newswire – 8:30 AM ET 01/08/2020

    LEXINGTON, Mass. Dr. Anthony El-Khoueiry of the USC Norris Comprehensive Cancer Center and Keck School of Medicine was the clinical investigator dosing this first patient. "AGEN1223 is a novel bispecific antibody designed to selectively deplete specific immune-suppressive cells called regulatory T cells.

Page:

Today's and Upcoming Events

  • May
    11

    AGEN to announce Q1 earnings (Unconfirmed)

Past Events (last 90 days)

  • Mar
    12

    AGEN announced Q4 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.